Coxsackie (virus) is a cytolytic virus of the Picornaviridae family, an enterovirus (a group containing the polioviruses, coxsackieviruses, and echoviruses). There are 61 non-polio enteroviruses that can cause disease in humans, of which 23 are Coxsackie A viruses (6 are Coxsackie B viruses). Enteroviruses are the second most common viral infectious agents in humans (after the rhinoviruses).
The Coxsackie viruses subsequently were found to cause a variety of infections, including epidemic pleurodynia (Bornholm disease), and were subdivided into groups A and B based on their pathology in newborn mice. (Coxsackie A virus causes paralysis and death of the mice, with extensive skeletal muscle necrosis; Coxsackie B causes less severe infection in the mice, but with damage to more organ systems, such as heart, brain, liver, pancreas, and skeletal muscles.)
The use of suckling mice was not Dalldorf's idea, but was brought to his attention in a paper written by Danish scientists Orskov and Andersen in 1947, who were using such mice to study a mouse virus. The discovery of the Coxsackie viruses stimulated many virologists to use this system and ultimately resulted in the isolation of a large number of so-called enteric viruses from the gastrointestinal tract that were unrelated to poliovirus, and some of which were oncogenic (cancer-causing).
The discovery of the Coxsackie viruses yielded further evidence that viruses can sometimes interfere with each other's growth and replication within a host animal. Other researchers found that this interference can be mediated by a substance produced by the host animal, a protein now known as interferon. Interferon has since become prominent in the treatment of a variety of cancers and infectious diseases.
Recently, Eastern China has been affected with the Coxsackie virus. It has been reported that 22 children have already died. More than 800 people have been affected, with 200 children already in the hospital.[1]
Selected papers:
1948 An unidentified, filtrable agent isolated from the feces of children with paralysis. Science 108:61-62.
1949 A virus recovered from the feces of "poliomyelitis" patients pathogenic for suckling mice. J. Exp. Med. 89:567-82. With G. M. Sickles. Serologic differences among strains of the Coxsackie group of viruses. Proc. Soc. Exp. Biol. Med. 72:30-31. The Coxsackie group of viruses. Science 110:594.
1951 With R. Gifford. Clinical and epidemiologic observations of Coxsackie virus infection. N. Engl. J. Med. 244:868-73. The sparing effect of Coxsackie virus infection on experimental poliomyelitis. J. Exp. Med. 94:65-71.
1952 With R. Gifford. Adaptation of group B Coxsackie virus to adult mouse pancreas. J. Exp. Med. 96:491-97.
1954 With R. Gifford. Susceptibility of gravid mice to Coxsackie virus infection. J. Exp. Med. 99:21-27.
1955 With R. Gifford. The recognition of mouse ectromelia. Proc. Soc. Exp. Biol. Med. 88:290-92. With R. Albrecht. Chronologic association of poliomyelitis and Coxsackie virus infections. Proc. Natl. Acad. Sci. USA 41:978-82.
1956 With S. Kelly. Antigenic potency of poliovirus vaccines. Am. J. Hyg. 64:243-58.
1957 The neuropathogenicity of group A Coxsackie viruses. J. Exp. Med. 106:69-76.